Zubrin

RSS
Withdrawn

This medicine's authorisation has been withdrawn

tepoxalin
MedicineVeterinaryWithdrawn
  • Application under evaluation
  • CVMP opinion
  • European Commission decision

Overview

The market authorisation for Zubrin has been withdrawn at the request of the marketing-authorisation holder.

español (ES) (511.13 KB - PDF)

View

čeština (CS) (595.78 KB - PDF)

View

dansk (DA) (510.17 KB - PDF)

View

Deutsch (DE) (513.33 KB - PDF)

View

eesti keel (ET) (510.33 KB - PDF)

View

ελληνικά (EL) (664.57 KB - PDF)

View

français (FR) (513.24 KB - PDF)

View

italiano (IT) (511.22 KB - PDF)

View

latviešu valoda (LV) (581.56 KB - PDF)

View

lietuvių kalba (LT) (536.1 KB - PDF)

View

magyar (HU) (589.67 KB - PDF)

View

Nederlands (NL) (510.07 KB - PDF)

View

polski (PL) (597.7 KB - PDF)

View

português (PT) (511.85 KB - PDF)

View

slovenčina (SK) (569.98 KB - PDF)

View

slovenščina (SL) (589.46 KB - PDF)

View

Suomi (FI) (510 KB - PDF)

View

svenska (SV) (509.65 KB - PDF)

View

Product information

български (BG) (1.39 MB - PDF)

View

español (ES) (354.35 KB - PDF)

View

čeština (CS) (876.13 KB - PDF)

View

dansk (DA) (361.88 KB - PDF)

View

Deutsch (DE) (380.8 KB - PDF)

View

eesti keel (ET) (353.43 KB - PDF)

View

ελληνικά (EL) (1.1 MB - PDF)

View

français (FR) (363.75 KB - PDF)

View

íslenska (IS) (608.9 KB - PDF)

View

italiano (IT) (369.61 KB - PDF)

View

latviešu valoda (LV) (919.36 KB - PDF)

View

lietuvių kalba (LT) (1.36 MB - PDF)

View

magyar (HU) (1.04 MB - PDF)

View

Malti (MT) (898.07 KB - PDF)

View

Nederlands (NL) (369.61 KB - PDF)

View

norsk (NO) (663.7 KB - PDF)

View

polski (PL) (696.28 KB - PDF)

View

português (PT) (370.61 KB - PDF)

View

română (RO) (907.36 KB - PDF)

View

slovenčina (SK) (1.1 MB - PDF)

View

slovenščina (SL) (738.16 KB - PDF)

View

Suomi (FI) (347.73 KB - PDF)

View

svenska (SV) (339.08 KB - PDF)

View
Latest procedure affecting product information: IB/0032
02/02/2012

español (ES) (243.72 KB - PDF)

View

čeština (CS) (768.39 KB - PDF)

View

dansk (DA) (243.34 KB - PDF)

View

Deutsch (DE) (460.26 KB - PDF)

View

eesti keel (ET) (15.67 KB - PDF)

View

ελληνικά (EL) (320.74 KB - PDF)

View

français (FR) (243.6 KB - PDF)

View

italiano (IT) (243.26 KB - PDF)

View

latviešu valoda (LV) (321.63 KB - PDF)

View

lietuvių kalba (LT) (304.46 KB - PDF)

View

magyar (HU) (308.89 KB - PDF)

View

Malti (MT) (322.75 KB - PDF)

View

Nederlands (NL) (243.75 KB - PDF)

View

polski (PL) (280.86 KB - PDF)

View

português (PT) (243.78 KB - PDF)

View

slovenčina (SK) (281.56 KB - PDF)

View

slovenščina (SL) (278.91 KB - PDF)

View

Suomi (FI) (240.48 KB - PDF)

View

svenska (SV) (244 KB - PDF)

View

Product details

Name of medicine
Zubrin
Active substance
tepoxalin
International non-proprietary name (INN) or common name
tepoxalin
Species
Dogs
Anatomical therapeutic chemical veterinary (ATCvet) code
QM01AE92

Pharmacotherapeutic group

Musculo-skeletal system

Therapeutic indication

Reduction of inflammation and relief of pain caused by acute and chronic musculoskeletal disorders.

Authorisation details

EMA product number
EMEA/V/C/000057
Marketing authorisation holder
Intervet International B. V.

Wim de Körverstraat 35
5831 AN Boxmeer
The Netherlands

Marketing authorisation issued
13/03/2001
Revision
13

Assessment history

This page was last updated on

Share this page